智通财经APP获悉，巨子生物(02367)涨超4%，截至发稿，涨4.31%，报50.85港元，成交额6198.34万港元。
消息面上，摩根士丹利研报指出，预期巨子生物未来15天股价有约70%至80%取得上升，并将其目标价定于65港元，给予“增持”评级。该行预计公司2024及2025财年的盈利增长，将分别为37%和23%，即将公布的全年业绩或较该行覆盖范围内的其他公司更强。
去年“双11”期间，巨子生物旗下两大品牌可复美及可丽金再次实现高增。根据公司“双11”战报，可复美与可丽金线上全渠道GMV分别同比增长80%+和150%+。浦银国际认为，公司两大品牌在“双11”大促期间高速的增长支撑公司达成全年盈利目标（收入和经调净利润分别同比提升略高于40%和35%左右）。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.